Pluristem Therapeutics Inc. is dedicated to the commercialization of
allogeneic (non-personalized) cellular therapeutics for disorders where
current therapies are inadequate.
Pluristem’s products begin as mesenchymal stromal cells (MSCs)
derived from human placenta, an organ traditionally considered
medical waste and a non-embryonic, non-controversial source
of cells. Pluristem’s MSCs are then grown in a unique (3D)
microenvironment (PluriX bioreactor), without the addition of growth
factors. The MSCs derived from this process are called PLacental
eXpanded (PLX) cells. PLX cells are functionally and immunologically
unique and are stored “ready to use” with no histocompatibility
PLX-PAD is intended to treat patients suffering from limb ischemia,
the critical stage of peripheral artery disease (PAD). PLX-PAD targets
those patients whom traditional therapies have not helped and are
potentially facing continued symptoms or amputation. In animals,
PLX-PAD has shown to significantly increase the number of new
blood vessels (angiogenesis) and blood flow in the involved extremity.
Pluristem plans for human studies to begin later in 2008.
PLX-I is intended to help those patients with hematological malignancies
that are unable to find a suitable bone marrow donor match. In animals,
PLX-I, combined with the HSCs found in umbilical cord blood (UCB), has
been shown to significantly increase the engraftment of these HSCs in
Pluristem believes its PLX cells are also potentially useful for other
disorders such as stroke, Multiple Sclerosis, Crohn’s Disease and
orthopedic injuries. Pluristem is an American public company with
headquarters housing its R&D and GMP-approved manufacturing
facilities in Haifa, Israel.